Selling, General, and Administrative Costs: Johnson & Johnson vs BioCryst Pharmaceuticals, Inc.

SG&A Expenses: A Decade of Divergence in Pharma Giants

__timestampBioCryst Pharmaceuticals, Inc.Johnson & Johnson
Wednesday, January 1, 2014746100021954000000
Thursday, January 1, 20151304700021203000000
Friday, January 1, 20161125300019945000000
Sunday, January 1, 20171393300021420000000
Monday, January 1, 20182951400022540000000
Tuesday, January 1, 20193712100022178000000
Wednesday, January 1, 20206792900022084000000
Friday, January 1, 202111881800020118000000
Saturday, January 1, 202215937100019046000000
Sunday, January 1, 202321389400020112000000
Monday, January 1, 202421969000000
Loading chart...

Unleashing insights

A Tale of Two Companies: SG&A Expenses Over Time

In the world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Johnson & Johnson and BioCryst Pharmaceuticals, Inc. have shown contrasting trends in their SG&A costs. From 2014 to 2023, Johnson & Johnson's SG&A expenses have remained relatively stable, fluctuating around $20 billion annually. In contrast, BioCryst Pharmaceuticals has seen a dramatic increase, with expenses rising from approximately $7 million in 2014 to over $213 million in 2023, marking a staggering 2,765% increase.

This divergence highlights the different scales and strategies of these companies. While Johnson & Johnson maintains a steady course, BioCryst's growth in SG&A expenses reflects its aggressive expansion and investment in new markets. Understanding these trends provides valuable insights into the operational strategies of these pharmaceutical giants.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025